Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLARITY-AFRICA: Cilostazol for Prevention of Recurrent Stroke in Africa
NCT06919835Phase 3Not yet recruiting
- Sponsor
- NCIRE - The Veterans Health Research Institute
- Start
- Aug 2026
- Primary completion
- Jul 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cilostazol in stroke, Transient Ischemic Attack (TIA), sponsored by NCIRE - The Veterans Health Research Institute. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
cilostazol
03
Conditions
strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06919835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06919835.